Bain Capital Life Sciences — Full Portfolio

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

RRRené Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKLKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Board seatAHAndrew Hack· per SEC Form D

Co-investorsBABay City CapitalF-F-Prime CapitalM M VenturesMRMRL Ventures FundRARA CapitalRIRiverVest Venture Partners+9 more

A Place for Mom is a senior care referral service that helps families find and compare senior living and care options, including assisted living, memory care, independent living, home care, nursing homes, and senior apartments.

ConsumerDigital HealthHealthtechMarketplacesWellness & FitnessVernon Hills, US

Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)

Co-investorsBABain Capital Double Impact Fund LPBABain Capital Tech OpportunitiesBABattery VenturesBEBessemer Venture PartnersBLBlue Sea CapitalBOBosch Ventures+38 more

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.

BiotechHealthtechMedical Devices

RFRichard F. Pops(Chairman of the Board, former CEO)Joshua Reed(Senior Vice President, Chief Financial Officer)inBCBlair C. Jackson(President & Chief Executive Officer)inDJDavid J. Gaffin(Executive Vice President, Chief Legal Officer and Chief Compliance Officer; Secretary)inCCCraig C. Hopkinson(Executive Vice President, Research and Development and Chief Medical Officer)C. Todd Nichols(Senior Vice President, Chief Commercial Officer)in

Co-investorsCACardinal PartnersVEVedanta CapitalHAHatteras Venture Partners

Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.

BiotechHealthtechCambridge, US

Justin Klee(Director)inJCJoshua Cohen(Founder)in

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

Co-investorsALAlpha Wave GlobalALALS Investment FundAVAvoro Capital Advisors

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

BiotechHealthtechMedical DevicesWestlake Village, US

Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)RSRicky Sun(Director)

BoardPHPatrick Heron(Director)inDEDaniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsFRFrazier Life SciencesRARA Capital

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)JHJanet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in

Co-investorsATATEM Capital FundRARA Capital

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

KCKenneth C. Anderson(Director)Andrew J. Hirsch(President and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investors3E3E Bioventures CapitalNENextech InvestRARA CapitalRORoche Venture FundCOCobro Ventures

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.

BiotechHealthtechRadnor, US

SNSteven Nichtberger(Founder)inDGDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)

BoardBDBrian Daniels(Director)in

Co-investors5A5AM VenturesDEDeerfield Management Company

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureFOForesite CapitalFRFrazier Life SciencesOROrbiMed5A5AM Ventures+7 more

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

RERiley Ennis(Founder)inCharles Roberts(Founder)inGOGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRARA CapitalAGAgent CapitalAMAME Cloud VenturesANAndreessen HorowitzARArtis VenturesASAsset Management Company+15 more

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US

CKChristopher K. Zarins(Executive Officer, Director)inCACharles A. Taylor(Executive Officer, Director)inNENicky Espinosa Hayes(Executive Officer)JSJohn Stevens(Executive Officer, Director)inH. Baird Radford, III(Executive Officer)JFJohn Farquhar(President, Chief Executive Officer & Director)in

Co-investors3S3Spoke CapitalBLBlue Venture FundsEMEmergent Medical Partners, LLPKHKhosla VenturesLILifeforce CapitalLOLotus Capital+3 more

Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.

BiotechHealthtechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)MEMarc Elia(Founder)inLynn Connolly(Executive Officer)inEric Kimble(Executive Officer)inHGHalley Gilbert(Executive Officer)inRDRebecca Dabora(Executive Officer)in

Co-investorsFOForesite CapitalGVGV (Google Ventures)MRMRL Ventures FundPRPremji InvestRARA CapitalFIFidelity Investments+6 more

Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.

Digital HealthHardwareHealthtechMedical Devices

BWBrian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTMTimothy Moran(Chief Business Officer)

Co-investorsANAndera PartnersLOLongitude CapitalSTStar51 CapitalBABain Capital

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures FundNENextech Invest+7 more

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.

BiotechEmeryville, US

WBWarner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)PMPeter Maag(Executive Officer, Director)in

Co-investorsVIVida VenturesWEWestlake Village BioPartnersGIGilead SciencesINInsight PartnersKLKleiner PerkinsNONorthpond Ventures+3 more

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

MRMatthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsCHCheyenne VenturesCLClaremont Creek VenturesFOForesite CapitalHAHarmony PartnersHBHBM Healthcare InvestmentsLILightspeed Venture Partners+4 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)CLCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsFOForesite CapitalLILightspeed Venture PartnersRARA CapitalWEWellington ManagementBIBiotechnology Value Fund+2 more

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsATAtlas VentureFOForesite CapitalREREDMILE

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsFOForesite CapitalGEGen CapitalGVGV (Google Ventures)ILIllinois VenturesNENextech InvestTHThe Column Group+2 more

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.

BiotechHealthtechMedical DevicesAustin, US

MPMatt Pauls(Chair of the Board of Directors and Chief Executive Officer)inMike Ciesla(Executive Officer)BCBadrul Chowdhury(Executive Officer)inSJSantosh J. Vetticaden(Executive Officer)Gregory D. Gorgas(Executive Officer)Patrick Keran(Executive Officer)

Co-investorsCECentral Texas Angel NetworkGRGreen Park & Golf VenturesKEKeiretsu ForumMOMoore Venture PartnersNENew Enterprise Associates (NEA)

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

BABobak Azamian(Founder)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)AMAziz Mottiwala(Chief Commercial Officer)inDWDianne Whitfield(Chief Human Resources Officer)inEYElizabeth Yeu-Lin(Chief Medical Officer)

Co-investorsAPAPERTURE Venture PartnersFLFlying L PartnersFRFrazier Life SciencesVIVisionary VenturesVIVivo CapitalRTRTW Investments L.P.

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)inAAAllison Ambrose(General Counsel)inADAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)AHAdam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsOROrbiMedACAccess IndustriesACAccess BiotechnologyDEDecheng CapitalHBHBM Healthcare InvestmentsHBHBM Partners+5 more

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

MDMary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)ACAdam Craig(Executive Officer, Director)in

Co-investorsLULumira VenturesNENew Enterprise Associates (NEA)PAPartners ResoluteTHThynk CapitalADAdvent Life SciencesOMOmega Funds+1 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsNENew Enterprise Associates (NEA)RARA CapitalSASamsara BioCapitalSASanofi VenturesMAMass General Brigham VenturesREREDMILE+9 more

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

ZLZhen Li(Co-founder, President & CEO)inRZRui Zhu(Founding Member & Chief Technology Officer)RARob Ackles(Chief People Officer)inRFRyan Fisk(Chief Financial Officer & Chief Business Officer)inRARobert A. MacLeod(Chief Scientific Officer)inCCChristopher Claeboe(Senior Vice President of Operations)in

Co-investorsOROrbiMedSRSR One Capital ManagementLILilly Asia VenturesT.T. Rowe PriceASAscenta CapitalTCTCG Crossover+3 more

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)MNMichael Naill(Senior Vice President, Process and Product Development)in

Co-investorsTHThird Rock VenturesGVGV (Google Ventures)BIBiotechnology Value FundTHThe Engine Ventures

Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsHBHBM PartnersSKSK Capital PartnersMÉMérieux Equity PartnersHBHBM Healthcare Investments

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)SBSteven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Board seatAHAndrew Hack· per SEC Form D

Co-investorsECEcoR1 CapitalFOForesite CapitalVIViking GlobalBABain CapitalRORock Springs CapitalT.T. Rowe Price

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seatAMAdam M. Koppel· per SEC Form D

Co-investorsFRFrazier Life SciencesLALatterell Venture PartnersLOLongitude CapitalOUOUP (Osage University Partners)AGAgent CapitalBABain Capital+3 more

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

RWRobin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in

BoardBenjamin Gomez(Director)AKAdam Koppel(Director)inMichael E. Bozik(Director)

Board seatAMAdam M. Koppel· per SEC Form D

Co-investorsARARCH Venture PartnersGVGV (Google Ventures)SOSolas BioVenturesVIViking GlobalACAccess BiotechnologyMAMaverick Capital+3 more

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)MGMatthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)SEScott Elliott(Executive Officer)in

BoardJames Rogers(Director)SEStacy Enxing Seng(Director)

Board seatAHAndrew Hack· per SEC Form D

Co-investorsASAscension VenturesCACatalio Capital Management, LPDEDelos CapitalFEFemHealth VenturesLILightstone Ventures

JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.

Digital HealthHealthtechMedical DevicesIrvine, US

HFHans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)John Kilcoynein

BoardAKArnd Kaltofen(Director)in

Board seatAHAndrew Hack· per SEC Form D

Co-investorsANAndera PartnersRORosetta Capital Ltd.VIVI PartnersATAtlas VentureGIGimvINInnovatus Capital Partners+5 more

Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies.

BiotechHealthtechMedical DevicesCambridge, US

MSMatthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)ABAlex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)

Board seatAHAndrew Hack· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsDEDeerfield Management CompanyVIViking GlobalWEWellington Management

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

AAAndrew Adamovich(Director)inPLPhilina Lee(Executive Officer, Director)inAPAaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsCACatalio Capital Management, LPPRProto AxiomSASanofi VenturesSVSV Health InvestorsTETenmileABAbingworth+2 more

Affera develops a medical technology platform for treating cardiac arrhythmias, including atrial fibrillation, using innovative ablation solutions.

HealthtechMedical DevicesNewton, US

DHDoron Harlev(CEO, Founder)in

Co-investorsBABAMCAPELElysia Capital

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsRARA CapitalSOSofinnova VenturesATAtlas VentureFOForbion

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

CQCarlos Quezada-Ruiz(Chief Medical Officer)in

Co-investorsSOSofinnova VenturesTCTCG CrossoverWEWellington Management

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

BiotechSouth San Francisco, US

Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)

Co-investorsFRFrazier Life SciencesLOLongitude CapitalVIViking GlobalBLBlackRockCACasdin CapitalFRFranklin Templeton+6 more

Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.

BiotechHealthtechMedical DevicesSo. San Francisco, US

Ben Barres(Scientific Co-Founder)DLDouglas Love(Founder)inMark L Smith(Executive Officer)CMCampbell Murray(Director)inThomas Wiggans(Director)RSRicky Sun(Director)

Co-investorsCOCorrelation VenturesNENew Enterprise Associates (NEA)BLBlackRockBLBlackstone Life SciencesCLClarus VenturesDEDeerfield Management Company+2 more

Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.

Sector AgnosticBoston, US

Co-investorsBABain Capital Double Impact Fund LPBABain Capital Tech OpportunitiesBCBCISDSDVACAccelBABain Capital+2 more

Bain Capital Credit is an investment firm specializing in credit strategies including liquid and structured credit, leveraged loans, high-yield bonds, CLOs, and direct lending to middle-market companies.

Fintech

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech Opportunities

Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.

Boston, US

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech OpportunitiesTWTwo Bear Capital

Bain Capital Real Estate is an investment firm focused on acquiring and operating real estate assets in niche, difficult-to-access sectors driven by long-term economic and secular trends.

PropTechBoston, US

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech Opportunities

Bain Capital Special Situations is a private investment firm that combines private equity, private credit, and asset-backed capital to source and structure specialized deals across asset classes.

FintechSector AgnosticHong Kong, HK

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech OpportunitiesFIFidelity InvestmentsGAGallatin Point Capital

Bain Capital Double Impact is an investment firm established in 2015 that funds companies generating both competitive financial returns and measurable social or environmental impact, with focus areas spanning healthcare access, economic opportunity, and environmental sustainability.

EdTechHealthtechImpact & Social Good

Co-investorsBABain CapitalBABain Capital Tech OpportunitiesBLBlue Haven Initiative

Beeline provides vendor management system (VMS) software for managing contingent and external workforces, including staffing suppliers and shift-based labor.

Future of WorkHR TechSaaS

Co-investorsACAcadian Ventures Management, Llc

Beeline Medicines is a biopharmaceutical company developing medicines for patients with serious diseases.

BiotechHealthtechMedical DevicesStamford, US

DBDr. Badreddin Edris(President and Chief Operating Officer)SISaqib Islam(Chief Executive Officer)inNFNathalie Franchimont(Chief Medical Officer)in

Co-investorsBABain Capital

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

MEMichael E. Mendelsohn(Founder and Chief Strategy Officer)in

Co-investorsBABain CapitalASAscenta CapitalDEDelos CapitalDIDigitalis VenturesNENew Enterprise Associates (NEA)BABain Capital Tech Opportunities+4 more

CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.

BiotechHealthtechMedical DevicesAuburndale, US

CHCarl Heilman(Director)DLDaniel Levangie(Executive Officer, Director)inLeslie Teso-Lichtman(Executive Officer)inFrederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

JSJeffrey Stein(Executive Officer, Director)KJKevin Judice(Director)inKevin Forrest(Executive Officer)DTDirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPDPaul Daruwala(Executive Officer)in

Co-investors5A5AM VenturesAIAisling CapitalFRFrazier Life SciencesRARA CapitalVIVivo CapitalCACanaan Partners+1 more

BiotechCambridge, US

CAChad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsLILifeSci Venture PartnersCACasdin CapitalVEVenrock Healthcare Capital Partners

Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJEJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)

Co-investorsAVAvoro Capital AdvisorsTHThe Column GroupVEVenrockTHThird Rock Ventures

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsACAccess BiotechnologyRIRidgeback CapitalOXOxford Bioscience PartnersRARA Capital

Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology.

BiotechHealthtechDüsseldorf, DE

RSRyan Spencer(Chief Executive Officer)inDNDavid Novack(President and Chief Operating Officer)inRJRobert Janssen(Chief Medical Officer and Senior Vice President, Clinical Development)inKMKelly MacDonald(Chief Financial Officer)inJCJeff Coon(Chief Human Resources Officer)DCDonn Casale(Chief Commercial Officer)in

Co-investorsHEHealthCapSASanderling Ventures

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechDigital Health

Co-investorsPAParagon Biosciences LLCVAValor Equity PartnersFIFidelity Investments

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechMedical Devices

Jeff Aronin(Founder)

Co-investorsPAParagon Biosciences LLCFIFidelity InvestmentsVAValor Equity Partners

FemTechHealthtechMedical DevicesRedwood City, US

Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)

BoardKen Haas(Director)JMJonathan MacQuitty(Director)inMCMike Carusi(Director)inDoug Fisher(Director)

Co-investorsAMAmzak HealthENEndeavour VisionFEFemHealth VenturesKAKaiser Permanente VenturesKLKluz VenturesLILightstone Ventures+6 more

Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.

AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US

AHAaron Hurst(Founder)in

Co-investorsEMEmpire AngelsGAGaingelsSASand Hill AngelsVOVoyager CapitalALAlly Bridge GroupAMAmed Ventures+6 more

InflaRx is a biopharmaceutical company developing therapeutics that target the complement system to treat inflammatory diseases.

BiotechHealthtechJena, DE

Renfeng Guo(Founder)in

Co-investorsRARA Capital

Bain Capital Insurance is the dedicated insurance investing and solutions arm of Bain Capital, making investments across the insurance value chain and growth spectrum.

FintechInsurTech

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech Opportunities

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)LFLori Forrest(Executive Officer)Leon Moulder, Jr.(Director)BLBenjamin Lund(Director)in

BoardTomas Kiselak(Director)

Co-investorsAGAgent CapitalDCDC Investment PartnersLOLongwood FundOUOUP (Osage University Partners)PFPfizer Venture InvestmentsQUQuan Capital+3 more

Bain Capital is a private equity investment firm with a Tokyo office that provides capital and strategic support to Japanese mid-market and large enterprises pursuing growth, restructuring, and business succession.

Enterprise SoftwareTokyo, JP

Co-investorsBABain CapitalBABain Capital Double Impact Fund LPBABain Capital Tech Opportunities

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)

Co-investorsAVAvalon BioVenturesPFPfizer Venture InvestmentsRARA CapitalPFPfizer VenturesPOPolaris PartnersVEVersant Ventures

Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureCACatalio Capital Management, LP

Longeviti Neuro Solutions develops cranial implant platforms for complex brain surgery, including patient-specific and off-the-shelf implants that restore skull contour and enable real-time post-operative ultrasound imaging.

HealthtechMedical Devices

JCJesse Christopher(CEO & Co-founder)in

Co-investorsMAMaryland TEDCOTETEDCO

BiotechRadnor, US

SBScott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)JHJoe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAVAvoro Capital AdvisorsCACanaan PartnersCOConnecticut InnovationsSOSofinnova VenturesDODomain AssociatesFLFlare Capital Partners+1 more

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inAPANNA PROTOPAPAS(Executive Officer, Director)TLTimothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsF-F-Prime CapitalLILightstone VenturesNENew Enterprise Associates (NEA)NENextech InvestPFPfizer Venture InvestmentsRHRho Ventures+3 more

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsBIBioGeneration VenturesEQEQT Life SciencesFRFrazier Life SciencesFOForbion

Nimbus Engineering is a hardware company and online retailer developing energy transfer technology, including its patented Power Relay, a portable power outlet for home, office, and outdoor use.

CleantechDeep TechEnergyHardwareSan Francisco, US

Michael Gorman(Founder)in

Co-investorsFOFoothill VenturesACAccess BiotechnologyATAtlas VentureBIBiotechnology Value FundCOCommodore CapitalGVGV (Google Ventures)+2 more

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPRPre-Seed to SucceedYEYellow Rocks!ACAccess BiotechnologyATAtlas VentureBIBiotechnology Value FundCOCommodore Capital+3 more

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsACAccess BiotechnologyATAtlas VentureDEDementia Discovery FundGVGV (Google Ventures)LILightstone VenturesPFPfizer Venture Investments+4 more

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDGDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsECEcoR1 CapitalFOForesite CapitalGEGeneral AtlanticSOSofinnova VenturesTHThe Column GroupWEWellington Management+1 more

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US

SKSri Kosuri(Founder)inRHRamsey Homsany(Founder)inRobert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)

Co-investorsANAndreessen Horowitz+N+ND Capital8V8VCCACarbon SiliconCACatalio Capital Management, LPEXExplorer Investments+10 more

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsFOForesite CapitalGEGeneral AtlanticKUKurma PartnersVEvenBio PartnersVIViking Global

Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.

BiotechDigital HealthHealthtechMedical DevicesNatick, US

Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)

Co-investorsCACatalio Capital Management, LPHBHB VenturesSOSoleus Capital

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)RMRoger M. Perlmutter(Executive Officer, Director)in

BoardJWJoshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)

Co-investorsCICisco InvestmentsFOForesite CapitalLULux CapitalDIDimension Capital

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)ACAllen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)JDJayson Dallas(Executive Officer, Director)inSKShaharyar Khan(Co-founder & Chief Scientific Officer)in

BoardFDFrancesco De Rubertis(Director)in

Co-investorsMEMedicxiLOLongitude CapitalRARA Capital

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)SMSusan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSASamsara BioCapitalTHThe Column GroupCACanaan PartnersRARA CapitalTCTCG CrossoverDEDeerfield Management Company+2 more

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsTHThird Rock VenturesGVGV (Google Ventures)

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Co-investorsAIAisling CapitalARARCH Venture PartnersQUQuan CapitalALAlexandriaALAlly Bridge GroupBABain Capital+11 more

Bain Capital Tech Opportunities is a technology-focused investment firm that provides growth capital, along with strategic and operational support, to entrepreneurs and management teams during expansion phases.

Enterprise SoftwareFintechSaaS

Co-investorsBABain CapitalBABain Capital Double Impact Fund LP

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.

BiotechMedical Devices

TETony Estrada(President & Chief Executive Officer; co-founder)in

Co-investorsARARCH Venture PartnersF-F-Prime CapitalDIDigitalis VenturesFOForbionMUMubadala Capital

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets.

BiotechHealthtech

Transforming the lives of patients through a functional cure for Type 1 Diabetes

BiotechSan Diego, US

Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)HFHoward Foyt(Executive Officer)inKevin D'Amour(Executive Officer)in

Co-investorsARArtis VenturesATATEL VenturesRARA CapitalSASanderling VenturesTHThe Vertical GroupJOJohnson & Johnson Innovation – JJDC+1 more